vs
Side-by-side financial comparison of ASCENT INDUSTRIES CO. (ACNT) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Intellia Therapeutics, Inc. is the larger business by last-quarter revenue ($23.0M vs $11.9M, roughly 1.9× ASCENT INDUSTRIES CO.). ASCENT INDUSTRIES CO. runs the higher net margin — -8.8% vs -416.2%, a 407.4% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 13.3%). ASCENT INDUSTRIES CO. produced more free cash flow last quarter ($-196.0K vs $-69.4M). Over the past eight quarters, Intellia Therapeutics, Inc.'s revenue compounded faster (-10.8% CAGR vs -34.9%).
ASCENT INDUSTRIES CO.ACNTEarnings & Financial Report
Ascent Capital Group, Inc. was a publicly traded holding company whose primary subsidiary was Monitronics. Ascent Media was a wholly owned subsidiary of the Discovery Holding Company (DHC). DHC spun off Ascent Media as an independent, public company on September 17, 2008.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
ACNT vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.9M | $23.0M |
| Net Profit | $-1.0M | $-95.8M |
| Gross Margin | 14.6% | — |
| Operating Margin | -21.0% | -428.9% |
| Net Margin | -8.8% | -416.2% |
| Revenue YoY | 13.3% | 78.8% |
| Net Profit YoY | -1.2% | 25.7% |
| EPS (diluted) | $-0.11 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.9M | $23.0M | ||
| Q3 25 | $19.7M | $13.8M | ||
| Q2 25 | $18.7M | $14.2M | ||
| Q1 25 | $24.7M | $16.6M | ||
| Q4 24 | $10.5M | $12.9M | ||
| Q3 24 | $20.9M | $9.1M | ||
| Q2 24 | $21.5M | $7.0M | ||
| Q1 24 | $28.0M | $28.9M |
| Q4 25 | $-1.0M | $-95.8M | ||
| Q3 25 | $-2.1M | $-101.3M | ||
| Q2 25 | $6.3M | $-101.3M | ||
| Q1 25 | $-2.3M | $-114.3M | ||
| Q4 24 | $-1.0M | $-128.9M | ||
| Q3 24 | $-6.2M | $-135.7M | ||
| Q2 24 | $-926.0K | $-147.0M | ||
| Q1 24 | $-5.5M | $-107.4M |
| Q4 25 | 14.6% | — | ||
| Q3 25 | 29.7% | — | ||
| Q2 25 | 26.1% | — | ||
| Q1 25 | 19.3% | — | ||
| Q4 24 | 24.3% | — | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 13.1% | — | ||
| Q1 24 | 8.3% | — |
| Q4 25 | -21.0% | -428.9% | ||
| Q3 25 | -4.1% | -808.9% | ||
| Q2 25 | -14.4% | -772.2% | ||
| Q1 25 | -4.2% | -726.6% | ||
| Q4 24 | -25.4% | -1059.9% | ||
| Q3 24 | -9.4% | -1589.0% | ||
| Q2 24 | -8.6% | -1998.6% | ||
| Q1 24 | -15.5% | -394.0% |
| Q4 25 | -8.8% | -416.2% | ||
| Q3 25 | -10.6% | -735.2% | ||
| Q2 25 | 33.7% | -710.8% | ||
| Q1 25 | -9.3% | -687.6% | ||
| Q4 24 | -9.8% | -1001.2% | ||
| Q3 24 | -29.5% | -1489.5% | ||
| Q2 24 | -4.3% | -2112.6% | ||
| Q1 24 | -19.7% | -371.3% |
| Q4 25 | $-0.11 | $-0.81 | ||
| Q3 25 | $-0.22 | $-0.92 | ||
| Q2 25 | $0.65 | $-0.98 | ||
| Q1 25 | $-0.23 | $-1.10 | ||
| Q4 24 | $-0.11 | $-1.27 | ||
| Q3 24 | $-0.61 | $-1.34 | ||
| Q2 24 | $-0.09 | $-1.52 | ||
| Q1 24 | $-0.54 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $57.6M | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $87.0M | $671.4M |
| Total Assets | $111.9M | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $57.6M | $449.9M | ||
| Q3 25 | $58.0M | $511.0M | ||
| Q2 25 | $60.5M | $459.7M | ||
| Q1 25 | $14.3M | $503.7M | ||
| Q4 24 | $16.1M | $601.5M | ||
| Q3 24 | $8.5M | $658.1M | ||
| Q2 24 | $3.6M | $691.1M | ||
| Q1 24 | $1.3M | $791.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $87.0M | $671.4M | ||
| Q3 25 | $87.1M | $748.4M | ||
| Q2 25 | $89.7M | $715.3M | ||
| Q1 25 | $91.2M | $779.9M | ||
| Q4 24 | $93.5M | $872.0M | ||
| Q3 24 | $94.7M | $962.6M | ||
| Q2 24 | $101.0M | $971.1M | ||
| Q1 24 | $102.0M | $1.0B |
| Q4 25 | $111.9M | $842.1M | ||
| Q3 25 | $119.9M | $925.3M | ||
| Q2 25 | $122.6M | $898.9M | ||
| Q1 25 | $152.5M | $986.2M | ||
| Q4 24 | $147.3M | $1.2B | ||
| Q3 24 | $148.6M | $1.2B | ||
| Q2 24 | $158.2M | $1.2B | ||
| Q1 24 | $161.0M | $1.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $266.0K | $-69.3M |
| Free Cash FlowOCF − Capex | $-196.0K | $-69.4M |
| FCF MarginFCF / Revenue | -1.7% | -301.6% |
| Capex IntensityCapex / Revenue | 3.9% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-2.1M | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $266.0K | $-69.3M | ||
| Q3 25 | $1.3M | $-76.9M | ||
| Q2 25 | $-1.4M | $-99.6M | ||
| Q1 25 | $-700.0K | $-148.9M | ||
| Q4 24 | $8.8M | $-85.2M | ||
| Q3 24 | $3.4M | $-84.8M | ||
| Q2 24 | $2.2M | $-58.2M | ||
| Q1 24 | $263.0K | $-120.7M |
| Q4 25 | $-196.0K | $-69.4M | ||
| Q3 25 | $695.0K | $-76.9M | ||
| Q2 25 | $-1.5M | $-99.9M | ||
| Q1 25 | $-1.0M | $-149.7M | ||
| Q4 24 | $8.4M | $-86.2M | ||
| Q3 24 | $3.1M | $-86.1M | ||
| Q2 24 | $1.9M | $-59.2M | ||
| Q1 24 | $25.0K | $-123.2M |
| Q4 25 | -1.7% | -301.6% | ||
| Q3 25 | 3.5% | -558.2% | ||
| Q2 25 | -8.3% | -701.0% | ||
| Q1 25 | -4.1% | -900.1% | ||
| Q4 24 | 80.6% | -669.4% | ||
| Q3 24 | 15.1% | -945.2% | ||
| Q2 24 | 9.1% | -850.9% | ||
| Q1 24 | 0.1% | -425.7% |
| Q4 25 | 3.9% | 0.5% | ||
| Q3 25 | 3.1% | 0.2% | ||
| Q2 25 | 0.8% | 1.7% | ||
| Q1 25 | 1.3% | 4.4% | ||
| Q4 24 | 3.7% | 7.6% | ||
| Q3 24 | 1.3% | 14.0% | ||
| Q2 24 | 1.0% | 14.5% | ||
| Q1 24 | 0.9% | 8.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.22× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACNT
| Other | $6.1M | 52% |
| Transferred At Point In Time | $5.7M | 48% |
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
